MiNK Q2 2026 net loss $3.1M, cash $8.8M; Phase 2 ALI data positive

MiNK Therapeutics, Inc.

Net loss $3.1M ($0.62/share) vs $4.2M ($1.06) in Q2 2025; six-month loss $5.9M vs $7.0M.
Cash $8.8M at June 30, 2026, down from $9.5M at March 31 and $13.4M at Dec 31, 2025.
Randomized Phase 2 (C-1300-02) in acute lung injury: first patients alive at Day 28, improved oxygenation, infection control, ventilator/vasopressor liberation; no major SAEs.
Established first paid international named-patient access program in Brazil via Orphan Drug Consulting for agenT-797.
Data presented at MHSRS; U.S. expansion underway, more data expected early 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.